The Effect of Rivandi Syrup on Non-Alcoholic Fatty Liver

Phase 3

• Conditions: on Alcoholic Fatty Liver.; Fatty (change of) liver, not elsewhere classified; K76.0

• Registration Number: IRCT20220529055009N1
• Lead Sponsor: Tehran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 7 February 2023

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

Non Alcoholic Fatty Liver Patients

Exclusion Criteria

Diabetes, Hypertension, Familial Hyper Lipedema, Chronic Heart Disease
Alcohol Use
Pregnancy, Lactation

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
CAP (Controlled Attenuation Parameter) Index in Fibroscan. Timepoint: 0 and 3 Months. Method of measurement: Fibroscan Device.;LSM (Liver Stiffness Measurement) in Fibroscan. Timepoint: 0 and 3 Months. Method of measurement: Fibroscan Device.

Secondary Outcome Measures

Name	Time	Method
Blood Serum Aspartate Transferase (AST). Timepoint: 0 and 3th months. Method of measurement: Blood Test.;Blood Test Alanine aminotransferase (ALT). Timepoint: 0 and 3th months. Method of measurement: Laboratory Blood Test.;Blood Test Alkaline phosphatase (ALP). Timepoint: 0 and 3th months. Method of measurement: Laboratory Blood Test.;Body Mass Index (BMI)= ratio of person's weight in kilograms and height in metres squared. Timepoint: 0 and 3th months. Method of measurement: Standard Scale.